AR048891A2 - Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv - Google Patents

Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv

Info

Publication number
AR048891A2
AR048891A2 ARP050101848A ARP050101848A AR048891A2 AR 048891 A2 AR048891 A2 AR 048891A2 AR P050101848 A ARP050101848 A AR P050101848A AR P050101848 A ARP050101848 A AR P050101848A AR 048891 A2 AR048891 A2 AR 048891A2
Authority
AR
Argentina
Prior art keywords
solution
weight
pharmaceutically acceptable
pharmaceutical composition
amount
Prior art date
Application number
ARP050101848A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25034589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048891(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR048891A2 publication Critical patent/AR048891A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Una composicion farmacéutica que es una solucion que comprende: (a) (2S, 3S, 5S)-2-(2,6-dimetilfenoxiacetil)amino-3-hidroxi-5-(2S-(1-tetrahidropirimid-2-onil)-3-metilbutanoil)amino-1,6-difenilhexano en la cantidad de, desde aproximadamente 1% a aproximadamente 50% en peso de la solucion total; (b) un solvente orgánico farmacéuticamente aceptable que comprende (i) un ácido graso de cadena larga farmacéuticamente aceptable de la cantidad de, desde aproximadamente 20% a aproximadamente 99%, en peso de la solucion total o (ii) una mezcla de (1) un ácido graso de cadena larga farmacéuticamente aceptable de desde 20% a aproximadamente99%, en peso de la solucion total y (2) un alcohol farmacéuticamente aceptable en la cantidad de, desde aproximadamente 0% a aproximadamente 15%, en peso de la solucion total; y (c) un surfactante farmacéuticamente aceptable en la cantidad de, desde aproximadamente 0% a aproximadamente 40%, en peso de la solucion total.
ARP050101848A 1996-11-21 2005-05-06 Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv AR048891A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75439096A 1996-11-21 1996-11-21

Publications (1)

Publication Number Publication Date
AR048891A2 true AR048891A2 (es) 2006-06-07

Family

ID=25034589

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970105444A AR010634A1 (es) 1996-11-21 1997-11-20 Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv
ARP050101848A AR048891A2 (es) 1996-11-21 2005-05-06 Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970105444A AR010634A1 (es) 1996-11-21 1997-11-20 Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv

Country Status (26)

Country Link
EP (2) EP0942721B1 (es)
JP (2) JP3592337B2 (es)
KR (2) KR100516567B1 (es)
CN (3) CN101103984A (es)
AR (2) AR010634A1 (es)
AT (1) ATE231393T1 (es)
AU (1) AU717546B2 (es)
BG (1) BG64411B1 (es)
BR (1) BR9714310A (es)
CA (2) CA2505430A1 (es)
CZ (1) CZ299728B6 (es)
DE (1) DE69718668T2 (es)
DK (1) DK0942721T3 (es)
ES (1) ES2191862T3 (es)
HK (1) HK1053787A1 (es)
HU (1) HU224319B1 (es)
IL (1) IL129300A (es)
NO (1) NO326927B1 (es)
NZ (1) NZ335002A (es)
PL (1) PL190185B1 (es)
PT (1) PT942721E (es)
SK (1) SK285022B6 (es)
TR (1) TR199901129T2 (es)
TW (1) TW475895B (es)
WO (1) WO1998022106A1 (es)
ZA (1) ZA9710071B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
KR100509130B1 (ko) * 1997-07-29 2005-08-18 파마시아 앤드 업존 캄파니 엘엘씨 친지성 화합물의 자가유화 제제
ATE225174T1 (de) 1997-07-29 2002-10-15 Upjohn Co Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
BR9811058A (pt) * 1997-07-29 2000-09-05 Upjohn Co Formulação auto-emulsificante para compostos lipofìlicos
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
EP1712231A3 (en) * 1998-11-04 2007-11-21 Pharmacia & Upjohn Company LLC Method for improving the pharmacokinetics of tipranavir
JP2002528502A (ja) * 1998-11-04 2002-09-03 ファルマシア・アンド・アップジョン・カンパニー チプラナビルの薬物動態を改善する方法
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
SI1183026T1 (sl) * 1999-06-04 2006-10-31 Abbott Lab Izboljsane farmacevtske spojine, vsebujoce ritonavir
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
AU2084801A (en) * 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
SI1248600T1 (sl) * 2000-01-19 2008-08-31 Abbott Lab Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
US6911214B2 (en) 2000-09-05 2005-06-28 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
CA2448438A1 (en) * 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
BR0202252A (pt) * 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
BR0302424A (pt) * 2003-07-23 2005-03-29 Cristalia Prod Quimicos Farm Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
EP1773850B1 (en) * 2004-07-06 2013-01-30 Abbott Laboratories Prodrugs of hiv protease inhibitors
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
CA2871794A1 (en) 2012-05-03 2013-11-07 Cipla Limited Antiretroviral composition
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9301447D0 (en) * 1990-11-19 1993-11-29 Monsanto Co Inhibitors of retrovirus protease
WO1993023388A1 (en) * 1992-05-20 1993-11-25 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
BR9206623A (pt) * 1991-10-11 1995-05-02 Du Pont Merck Pharma Uréias cíclicas e análogas úteis como inibidoras da protease retroviral
IL103613A (en) * 1991-11-08 1999-05-09 Merck & Co Inc VIH protease inhibitors, and the process of preparing intermediates and pharmaceutical preparations containing them.
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ATE143262T1 (de) * 1992-12-29 1996-10-15 Abbott Lab Inhibitoren der retroviralen protease
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
NO992427D0 (no) 1999-05-20
AR010634A1 (es) 2000-06-28
ATE231393T1 (de) 2003-02-15
WO1998022106A1 (en) 1998-05-28
CN1248914A (zh) 2000-03-29
DK0942721T3 (da) 2003-05-19
CN101103984A (zh) 2008-01-16
CA2271196C (en) 2005-06-28
ES2191862T3 (es) 2003-09-16
KR20040004426A (ko) 2004-01-13
CA2505430A1 (en) 1998-05-28
AU717546B2 (en) 2000-03-30
JP2000515555A (ja) 2000-11-21
SK65599A3 (en) 1999-12-10
CN1989963B (zh) 2011-06-29
CZ160299A3 (cs) 1999-08-11
AU5257398A (en) 1998-06-10
CZ299728B6 (cs) 2008-11-05
TR199901129T2 (xx) 2001-05-21
NZ335002A (en) 2001-08-31
EP0942721B1 (en) 2003-01-22
BR9714310A (pt) 2000-05-02
NO992427L (no) 1999-07-20
BG103425A (en) 2000-04-28
CN1250219C (zh) 2006-04-12
TW475895B (en) 2002-02-11
KR20000057169A (ko) 2000-09-15
IL129300A (en) 2003-07-06
SK285022B6 (sk) 2006-04-06
PL190185B1 (pl) 2005-11-30
DE69718668T2 (de) 2003-10-02
HU224319B1 (hu) 2005-07-28
HK1053787A1 (zh) 2003-11-07
JP3592337B2 (ja) 2004-11-24
KR100516567B1 (ko) 2005-09-22
KR100478075B1 (ko) 2005-03-23
BG64411B1 (bg) 2005-01-31
NO326927B1 (no) 2009-03-16
PL336980A1 (en) 2000-07-31
CN1989963A (zh) 2007-07-04
DE69718668D1 (de) 2003-02-27
CA2271196A1 (en) 1998-05-28
HUP0002932A2 (hu) 2001-01-29
JP4523799B2 (ja) 2010-08-11
JP2004346077A (ja) 2004-12-09
EP0942721A1 (en) 1999-09-22
PT942721E (pt) 2003-06-30
IL129300A0 (en) 2000-02-17
ZA9710071B (en) 1998-05-25
EP1283041A1 (en) 2003-02-12
HUP0002932A3 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
AR048891A2 (es) Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
YU39800A (sh) Derivati sulfonamida kao pro-lekovi inhibitora aspartil proteaze
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
DE69434626D1 (de) Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
AR062931A2 (es) Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
TR200002159T2 (tr) NSAI ilaçların verilmesi için topikal bileşimler.
AR090603A2 (es) Composicion parenteral y procedimiento para su preparacion
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
CO5070655A1 (es) El compuesto (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil)amino-3-hidroxi-5-[2s-(1-tetrahidro- pirimid-2-onil)-3-metilbutanoil]amino-1,6-difenilhexano, proceso para su preparacion y formulaciones farmaceuticas que lo contienen
PE20021017A1 (es) Composicion parenteral reconstituible
AR039688A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
AR064309A2 (es) Composicion farmaceutica de ritonavir
DE69328192D1 (de) Injizierbare Arzneizubereitungen enthaltend Taxanderivate
UY24386A1 (es) Nuevos taxoides, su preparación y composiciones farmacéuticas que los contienen.
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
BR0007584A (pt) Polimorfos de telmissartano, processos para preparação dos mesmos e seu uso na preparação de uma composição farmacêutica
CO5070569A1 (es) Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
EP0135171A3 (en) Pharmaceutical composition for interferon application
IT1264857B1 (it) Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico
AR031358A1 (es) Combinacion de inhibidores de calpaina y secuestrantes de especies de oxigeno reactivo
ES2161247T3 (es) Preparacion vaginal que contiene un peptido fisiologicamente activo.
PT92649A (pt) Processo para a preparacao do 4-fluoro-2-< { (4-metoxi-2-piridinil)-metil}-sulfinil>-1h-benzimidazol e de composicoes farmaceuticas que o contem

Legal Events

Date Code Title Description
FB Suspension of granting procedure